



Availability of suPAR in emergency departments may improve risk stratification a secondary analysis of the TRIAGE III trial

Schultz, Martin; Rasmussen, Line J. H.; Kallemose, Thomas; Kjølner, Erik; Lind, Morten N.; Ravn, Lisbet; Lange, Theis; Kober, Lars; Rasmussen, Lars S.; Eugen-Olsen, Jesper; Iversen, Kasper

Published in:

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine

DOI:

[10.1186/s13049-019-0621-7](https://doi.org/10.1186/s13049-019-0621-7)

Publication date:

2019

Document version

Publisher's PDF, also known as Version of record

Document license:

[CC BY](#)

Citation for published version (APA):

Schultz, M., Rasmussen, L. J. H., Kallemose, T., Kjølner, E., Lind, M. N., Ravn, L., Lange, T., Kober, L., Rasmussen, L. S., Eugen-Olsen, J., & Iversen, K. (2019). Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*, 27, [43]. <https://doi.org/10.1186/s13049-019-0621-7>

ORIGINAL RESEARCH

Open Access



Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial

Martin Schultz^{1,2*} , Line J. H. Rasmussen³, Thomas Kallemose³, Erik Kjølner¹, Morten N. Lind⁴, Lisbet Ravn⁴, Theis Lange^{5,6}, Lars Køber⁷, Lars S. Rasmussen⁸, Jesper Eugen-Olsen³ and Kasper Iversen¹

Abstract

Introduction: Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic and nonspecific biomarker associated with short-term mortality in emergency department (ED) patients. Therefore, the blood level of suPAR might be usable for identification of patients at high- and low risk, shortly after arrival at the ED. Here, we investigate the value of adding suPAR to triage and how this may impact on risk stratification regarding mortality.

Methods: The analyses were performed on the TRIAGE III cohort. Patients were triaged in four groups: Red, Orange, Yellow, and Green. Outcome was all-cause mortality within seven days. Discriminative abilities of triage and suPAR on mortality were assessed using the area under the curve (AUC) for receiver operating characteristics (ROC) curves. A suPAR cut-off value was generated using the Youden's index. Patients were subsequently reclassified one triage level up if the suPAR level was above this cut-off and one level down if the suPAR level was below that value.

Results: The study included 4420 patients with an available triage category and suPAR measurement. suPAR was significantly better in predicting mortality than triage; AUC (95% confidence interval): 0.85 (0.80–0.89) vs. 0.71 (0.64–0.78), $P < 0.001$. Combining suPAR and triage yielded an AUC of 0.87 (0.82–0.93). The Youden's cut-off of suPAR was 5.9 ng/mL and reclassified triage using this value resulted in a more accurate risk stratification regarding hospital admission and mortality.

Conclusion: Addition of suPAR to triage potentially improves prediction of short-term mortality. Measurement of suPAR in relation to the triage process may allow a more accurate identification of ED patients at risk.

Trial registration: [Clinicaltrials.gov](https://clinicaltrials.gov), NCT02643459. Registered 31 December 2015. <https://clinicaltrials.gov/ct2/show/NCT02643459?cond=NCT02643459&rank=1>.

Keywords: Emergency department, Triage, Risk stratification, Prognostic biomarkers, suPAR

* Correspondence: Martin.schultz@regionh.dk

¹Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Ringvej 75, 2730 Herlev, Denmark

²Department of Internal medicine and Geriatrics, Herlev and Gentofte Hospital, University of Copenhagen, Ringvej 75, 2730 Herlev, Denmark

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Triage is the process of quickly assessing and prioritising patients according to urgency and need for treatment [1]. Most emergency departments (ED) use risk scoring systems to perform triage, [1, 2] and widely used conventional triage algorithms are 5-level scales relying on measurements of vital signs and the presenting complaint [1, 2]. Blood tests can also be included, [3, 4] and risk stratification models using various biomarkers have been shown to have high discriminative powers regarding mortality in patients arriving at the EDs [5, 6].

The protein soluble urokinase plasminogen activator receptor (suPAR) is a nonspecific biomarker that contains information on presence and severity of a broad variety of acute and chronic diseases. In addition, the suPAR level is associated with length of stay and transfer to the intensive care unit in patients presenting acutely to the EDs, as well as an independent predictor of short-term mortality [7–9]. Therefore, suPAR is a potential candidate to improve the accuracy in the triage process, however the impact of adding suPAR has not previously been explored.

The present study aimed to investigate if adding suPAR to conventional triage would improve accuracy prediction of mortality and how this may impact risk stratification.

Methods

Setting and design

The TRIAGE III trial was a cluster-randomised interventional trial investigating the effect of introducing suPAR as a routine biomarker in the ED. In this study, we performed post hoc secondary analyses investigating the effect of adding suPAR to triage in outcome prediction. The TRIAGE III trial collected data from an unselected population admitted to EDs at hospitals in Denmark. The two participating hospitals have large EDs with access to all medical specialities, general, and orthopaedic surgery, as well as intensive care, and manage 70,000 and 85,000 annual patient visits. Both are university hospitals with a catchment population of approximately 425,000 and 480,000 respectively of mostly city areas. In interventional periods suPAR measurement was available within 30–120 min of arrival alongside routine blood tests at acute admission (analysis of suPAR took 23 min using point-of-care equipment). In control periods suPAR was unavailable. In the current study, we included patients' first ED visit where both the suPAR level was determined and a triage category was recorded. The protocol and primary results have been published [10, 11].

The EDs use the conventional triage algorithm “Danish Emergency Process Triage” (DEPT) [12], which consist of measurements of vital signs (blood pressure, heart rate, level of consciousness, arterial oxygen saturation,

respiratory rate, and temperature), as well as an assessment of the presenting complaint. DEPT is a local variant of Adaptive process triage (ADAPT) [13]. The triage algorithm categorise patients into five groups: Red (most urgent), Orange, Yellow, Green (least urgent), and Blue (minor injuries) [14]. There were few patients triaged Blue ($N = 103$), and as they were similar to the patients in the Green category, Green and Blue categories were combined in these analyses.

Analyses

Hospital admission was defined as a stay in the ED of more than 24 h or transfer from the ED to a stationary ward. This definition was necessary as patients arriving at the EDs are registered differently in the hospital records upon arrival (medical patients are registered as admitted even though some were discharged shortly after arrival). Length of stay were calculated in all hospital admissions. In the analysis, we sought to assess the ability to improve prediction of seven-day all-cause mortality by adding the suPAR level at arrival to the initial triage level. First, we assessed the discriminative ability of suPAR in predicting seven-day mortality using area under the curve (AUC) for receiver operating characteristics (ROC) curves.

Then, we identified a cut-off value of suPAR and used this threshold to reclassify patients one level up in triage category, if suPAR was above the threshold and one level down in triage category if the suPAR value was below the threshold.

Statistics

Continuous variables are presented with median and interquartile range (IQR), or mean and standard deviation (SD) and compared using Wilcoxon Rank-sum test and Student's two-sample t-test. Categorical variables are described as number (n) and percentage (%) and compared using chi-square test. The discriminative ability of triage and suPAR to predict seven-day all-cause mortality was analysed using AUC for ROC curves. Comparison of AUCs was done using the Delong method [15]. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated from cut-off based on the Youden's index in a ROC analyses using a logistic regression [16]. Comparison of initial triage and reclassification was done using McNemar's test and Fischer's exact test. A P -value of < 0.05 was considered significant. Statistics were performed in R version 3.4.1 [17, 18].

Results

Of 16,801 unique patients from the TRIAGE III population, the triage category was available in 9082 (54.1%) patients. In patients with triage categories 4420 (48.7%) arrived in interventional periods and had a suPAR level

available, thus comprising the study population (Additional file 1: Figure S1). The mean age (SD) was 59.6 (20.8) years, and 2239 (50.7%) were women, and 2108 (47.7%) were admitted. The median (IQR) suPAR level was 3.9 ng/mL (2.9–5.8). At seven days 58 (1.3%) patients had died. Baseline characteristics are displayed in Table 1. Patients where no triage category was available were significantly older (61.6 vs 59.7 years, $P < 0.001$), more were women (55.5% vs 50.7, $P < 0.001$) and more were admitted (52.2% vs. 47.7%, $P < 0.001$), but there was no significant difference in all-cause mortality at seven days (1.6% vs 1.3%, $P = 0.268$).

The number of patients in the triage categories were: Red: 215 (4.9%), Orange: 1241 (28.1%), Yellow: 1243 (28.1%), and Green: 1721 (38.9%). The suPAR level increased with more urgent triage categories and was significantly higher in non-survivors compared to survivors across all categories ($P < 0.001$).

Discriminative abilities of suPAR in predicting seven-day mortality in all patients were significantly higher than DEPT triage; AUC (95% CI): 0.85 (0.80–0.89) vs. 0.71 (0.64–0.78), $P < 0.001$. In comparison, age had a AUC of 0.78 (0.74–0.83). Combining suPAR and DEPT yielded an


AUC of 0.87 (0.82–0.93), which was not significantly higher than suPAR alone ($P = 0.16$), Fig. 1. A model with the addition of both suPAR and age to DEPT were not significantly better than suPAR alone ($P = 0.16$) or suPAR and DEPT ($P = 0.10$). suPAR had consistently high discriminative ability for seven-day mortality in all triage groups. (Fig. 2). The AUC for predicting hospital admission for DEPT was 0.60 (0.58–0.61) compared to the combination of DEPT and suPAR: 0.86 (0.82 to 0.91), $P < 0.01$. The optimal cut-off (threshold) for discriminating between survivors and non-survivors among all patients was 5.9 ng/mL (specificity: 0.77, sensitivity: 0.79, PPV: 0.05, NPV: 1.0). In the study population 3372 (76.3%) patients had a suPAR level below the threshold at arrival to the ED. Sensitivity analyses showed that a cut-off ranging from 5.5 ng/mL to 6.4 ng/mL performed equally well and yielded qualitatively same results.

Reclassification into new triage categories was then done according to a suPAR level above or below 5.9 ng/mL, Table 2. The reclassified triage had significantly more patients in the most urgent triage category (Red) compared to DEPT (9.0% vs. 4.9%, $P < 0.001$), significantly less patients in the Orange category (10.1% vs 28.1% $P < 0.001$),

Table 1 Baseline characteristics of patients at arrival at the emergency departments. Patients are grouped according to the initial triage category

Triage category <i>N</i> (%)	Included 4420 (100)	Red 215 (4.9)	Orange 1241 (28.1)	Yellow 1,243 (28.1)	Green 1721 (38.9)
Female sex, <i>N</i> (%)	2239 (50.7)	92 (42.8)	643 (51.8)	602 (48.4)	902 (52.4)
Age, years, mean (SD)	59.7 (20.8)	62.3 (21.5)	63.5 (19.2)	60.5 (20.7)	55.9 (21.3)
Albumin, (g/L), median (IQR)	39 (35–43)	36 (32–40)	37 (33–40)	39 (34–43)	41 (38–44)
CRP (mg/L), median (IQR)	4 (3–32)	5 (3–33)	3 (3–23)	5 (3–35)	4 (3–41)
suPAR, ng/mL, median (IQR)	3.9 (2.9–5.8)	5.6 (3.4–7.1)	4.1 (2.9–6.0)	3.9 (2.9–5.9)	3.8 (2.8–5.4)
suPAR, patients alive at seven days, ng/mL, median (IQR)	3.9 (2.9–5.7)	4.8 (3.2–6.5)	4.1 (2.9–6.0)	3.9 (2.9–5.8)	3.8 (2.8–5.4)
suPAR, patients dead at seven days, ng/mL, median (IQR)	8.6 (6.0–12.8)	7.9 (5.9–9.7)	10.9 (8.1–15.0)	7.9 (6.3–11.1)	9.8 (5.3–14.7)
Cancer, <i>N</i> (%)	166 (3.8)	9 (4.2)	41 (3.3)	46 (3.7)	70 (4.1)
Cardiovascular disease, <i>N</i> (%)	956 (21.6)	79 (36.7)	419 (33.8)	239 (19.2)	219 (12.7)
Infectious disease, <i>N</i> (%)	830 (18.8)	50 (23.3)	207 (16.7)	228 (18.3)	345 (20.0)
Neurological disease, <i>N</i> (%)	341 (7.7)	27 (12.6)	117 (9.6)	99 (8.0)	98 (5.7)
General surgery, <i>N</i> (%)	168 (3.8)	6 (2.8)	26 (2.1)	54 (4.3)	82 (4.8)
Orthopaedic surgery, <i>N</i> (%)	154 (3.5)	1 (0.5)	102 (8.2)	26 (2.1)	25 (1.5)
Other, <i>N</i> (%)	1805 (40.8)	43 (20.0)	329 (26.5)	551 (44.3)	882 (51.2)
Herlev Hospital, <i>N</i> (%)	2780 (62.9)	85 (3.1)	628 (22.6)	683 (24.6)	1384 (49.8)
Bispebjerg Hospital, <i>N</i> (%)	1640 (37.1)	130 (8.0)	613 (37.3)	560 (34.2)	337 (20.5)
Hospital admission, <i>N</i> (%)	2108 (47.7)	143 (66.5)	706 (56.9)	615 (49.5)	644 (37.4)
Length of stay (days), mean (SD)	4.2 (7.1)	7.0 (11.1)	5.1 (7.9)	4.1 (6.2)	3.3 (6.2)
Surgery during admission, <i>N</i> (%)	444 (10.0)	15 (7.0)	164 (13.2)	112 (9.0)	153 (8.9)
Readmissions at seven days, <i>N</i> (%)	238 (5.4)	10 (4.7)	72 (5.8)	72 (5.8)	84 (4.9)
Mortality at seven days, <i>N</i> (%)	58 (1.3)	17 (7.9)	20 (1.6)	12 (1.0)	9 (0.5)

CRP C-Reactive Protein, IQR Interquartile range, SD standard deviation, suPAR Soluble urokinase plasminogen activator receptor



same number of patients in the Yellow ($P = 0.968$), and finally significantly more patients classified in the least urgent triage (Green) category compared to DEPT (52.3% vs. 38.9%, $P < 0.001$). The patients allocated to the Green category in the reclassified triage were significantly younger ($P = 0.002$) compared to DEPT, while the patients in the remaining categories were significantly older in the reclassified triage (Yellow: $P = 0.002$, Orange: $P < 0.001$, Red: $P < 0.001$), Table 2.

After reclassification, significantly more patients were admitted in the Red and Orange category ($P < 0.001$), with a significantly higher mortality in Orange ($P = 0.028$) but not in Red ($P = 0.997$). While the Yellow categories remained unchanged (mortality: $P = 0.676$, admission: $P = 0.109$), the Green category in the reclassified triage had had more patients, but the same hospital admission rates ($P = 0.579$), and mortality ($P = 0.190$). The predictive ability of the reclassified triage was significantly better than DEPT in discriminating between survivors and non-survivors at seven days; AUC (95% CI) 0.81 (0.76–0.87) vs. 0.71 (0.64–0.78), $P < 0.001$.

Discussion

This study demonstrated that addition of suPAR to the conventional triage algorithm DEPT may improve the discriminative ability regarding in seven-day mortality in a cohort of acutely presenting medical and surgical patients. We also found a clinically transferable cut-off of 5.9 ng/ml allowing a more accurate risk stratification according to


mortality risk. Also, reclassification according to the suPAR level resulted in triage categories with a better risk stratification in relation to hospital admission and mortality compared to DEPT.

The predictive abilities of suPAR were good in all triage categories apart from Red, and in accordance with previous reports of suPAR in emergency medicine, [7, 9] demonstrating a robust and high discriminative ability in relation to all-cause mortality in unselected patients arriving at the ED. The predictive ability of suPAR is equal to or better than age and other scoring systems designed to assess patients in the ED [19]. The investigated cohort consist of a large spectrum of patients arriving around the clock and suffering from both medical and surgical conditions, making this cohort suitable for testing the impact of a non-specific biomarker in relation to overall risk stratification.

However, it has not been determined whether use of a prognostic biomarker for risk stratification in the ED translates into meaningful and prognosis-changing interventions. A risk scoring system useful in emergency medicine must be simple, easily obtainable and quickly translatable to clinical decision making. One limitation of using suPAR is the need for blood sampling and analysis before the level is obtained, hence reclassification would be delayed. We used point-of-care equipment which is currently the fastest available way to analyse suPAR, however, the delay might make the suPAR level redundant in patients where treatment must be initiated immediately or within a short time frame. However, in situations with crowding, the suPAR level could be beneficial in prioritizing patients in the lower urgency classes (Yellow and Green), who might not need immediate action. This is the case of the majority of patients in the EDs and identification of those in need of a higher level of observation and faster assessment of the physician could be beneficial. This reclassification stay could potentially improve management, flow, and treatment of patients, but this must be further assessed in randomised interventional studies.

Limitations

The study has several limitations. The analyses are done post hoc and do not include patients with gynaecological or obstetric conditions, trauma patients or patients where blood samples were not indicated. The purpose of triage algorithms is to prioritize according to urgency, however as no gold standard for urgency exists, we used surrogate endpoints. We did not have data to assess other important endpoints as time to treatment, need for antibiotic, iv fluids or imaging, which is also a limitation. Furthermore, using mortality as a measure, also includes patients with terminal illness in high urgency groups, who might not need fast assessment or continuous observation,



however, patients with a very high risk of short-term mortality should ideally be assessed by a physician shortly after arrival. There was a low mortality rate at seven days, which introduce some uncertainties in the analyses. The cut-off value and subsequent reclassification was done using the same patients, and the cut-off should be validated in more cohorts of ED patients before clinical use. Another important limitation is the fact that the proportion of patients in the Red category almost doubled in the reclassified triage, which might cause flow issues and tie up personnel and resources. However, a subsequent reclassification of patients in the Red and Orange categories could be used to indicate

where the most attention should be directed and ensure a high level of observation. The Danish EDs are currently using a local version of the National Early Warning Score (NEWS) for this purpose after the initial triage. It has previously been shown that addition of suPAR to NEWS improves risk prediction in both high- and low risk patients [20]. In this study, we used the Youden index for calculating the suPAR cut-off to maximize both sensitivity and specificity, as it depends on the clinical setting, whether a rule-in or a rule-out strategy is required. However, a different strategy could be use of a cut-off with the highest possible sensitivity for ruling out patients in risk of short-term

Table 2 Reclassification of triage categories according to the suPAR level measured at arrival

Triage category <i>N</i> (%)	Red 396 (9.0) ^a	Orange 445 (10.1) ^a	Yellow 1.267 (28.7)	Green 2312 (52.3) ^a
Female sex, <i>N</i> (%)	209 (52.8)	202 (45.4)	665 (52.5)	1163 (50.3)
Age, years, mean (SD)	74.8 (14.6) ^a	67.6 (20.0) ^a	62.8 (19.0) ^a	53.8 (20.6) ^a
Hospital admission, <i>N</i> (%)	324 (81.8) ^a	304 (68.3) ^a	665 (52.5)	815 (35.2)
Length of stay (days), mean (SD)	8.5 (11.8)	6.9 (9.5) ^a	4.6 (7.3)	2.8 (4.3) ^a
Surgery during admission, <i>N</i> (%)	64 (16.2) ^a	42 (9.4) ^a	135 (10.6)	203 (8.8)
Readmissions at seven days, <i>N</i> (%)	33 (8.3)	30 (6.7)	72 (5.9)	103 (4.5)
Mortality at seven days, <i>N</i> (%)	28 (7.1)	14 (3.1) ^a	10 (0.8)	6 (0.3)

SD: standard deviation ^aSignificantly different from the initial triage category

mortality. Additionally, using multiple cut-offs (e.g. tertiles) might have a different impact on the reclassified triage, we chose the single cut-off for simplicity reasons making suPAR easy to implement in a future study. Patients without an available triage category were not included, which might represent a potential source of bias. Furthermore, our results might not be transferable to triage algorithms different from DEPT and the additive prognostic abilities of suPAR should be explored in addition to other algorithms as well. Finally, no randomised interventional studies to date have demonstrated that improved triage or risk scoring systems using prognostic biomarkers leads to a better prognosis. The TRIAGE III study aimed to investigate if early risk stratification using suPAR would improve patient prognosis, but found no effect on mortality, however there was no specific intervention and the suPAR level was not available at the time of triage.

Conclusion

Addition of the prognostic biomarker suPAR to triage potentially improves prediction of seven-day mortality in the emergency department. Measurement of suPAR in relation to the triage process may allow a more accurate identification of ED patients at high and low risk of short-term mortality and enable a subsequent reclassification of patients.

Additional file

Additional file 1: Figure S1. Flowchart of the TRIAGE III trial. The population included in these secondary analyses were patients arriving in the interventional periods, who had an available suPAR level and triage category. (PDF 123 kb)

Funding

The TRIAGE III trial was investigator-initiated and was supported by an unrestricted grant from ViroGates A/S, the company that produces the suPARnosic assays. The company nor the CEO had any influence on the design of these secondary analyses of the TRIAGE III trial, and was not involved in data collection, analysis, or interpretation, in the writing of the manuscript, or in the decision to submit the manuscript for publication. JE-O contributed to the interpretation of this study and revised the manuscript, but he did not have influence on the design, included analyses, nor the decision to submit.

Availability of data and materials

The dataset supporting the conclusion of this article is available from the corresponding author upon reasonable request and conditioned by acceptance of a formal request by the Danish Data Protection Agency according to Danish law.

Authors' contributions

MS designed this study and conducted the statistical analyses, created the figures, and wrote the first draft of the manuscript. All authors contributed substantially to the interpretation of the results, to critical revisions, and approved the final version of the manuscript.

Ethics approval and consent to participate

The Danish Data Protection Agency approved the TRIAGE III trial (HGH-2015-042, I-Suite no. 04087) as well as the Danish Patient Safety Authority (Ref.no. 3–3013-1744/1). The trial was presented to the Regional Ethics Committee, who decided that no formal approval was needed for the cluster-randomised TRIAGE III trial,

and that it could be conducted without consent of the patients in accordance with Danish law (Ref.no. FSP-15003590). No further permissions were required for these secondary analyses.

Consent for publication

Not applicable.

Competing interests

MS and LJHR have received funding for travel from ViroGates A/S, Denmark. JE-O is named as an inventor in patents for the use of suPAR as a prognostic biomarker. The patents are owned by Copenhagen University Hospital, Amager and Hvidovre, Denmark, and are licensed to ViroGates A/S. JE-O is co-founder, shareholder, and CSO of ViroGates A/S. The remaining authors have no conflicts of interest to declare.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Ringvej 75, 2730 Herlev, Denmark. ²Department of Internal medicine and Geriatrics, Herlev and Gentofte Hospital, University of Copenhagen, Ringvej 75, 2730 Herlev, Denmark. ³Clinical Research Centre, Amager and Hvidovre Hospital, University of Copenhagen, Kettegård Alle 30, 2650 Hvidovre, Denmark. ⁴Department of Emergency Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Herlev ringvej 75, 2730 Herlev, Denmark. ⁵Department of Public Health, University of Copenhagen, Section of biostatistics, Øster Farimagsgade 5, 1014 Copenhagen, Denmark. ⁶Center for Statistical Science, Peking University, No. 5 Yiheyuan Road Haidian District, Beijing 100871, China. ⁷Department of Cardiology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark. ⁸Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Received: 4 October 2018 Accepted: 26 March 2019

Published online: 11 April 2019

References

1. Farrokhi N, Castrén M, Ehrenberg A, Lind L, Oredsson S, Jonsson H, et al. Emergency department triage scales and their components: a systematic review of the scientific evidence. *Scand J Trauma Resusc Emerg Med.* 2011;19:42.
2. Kuriyama A, Urushidani S, Nakayama T. Five-level emergency triage systems: variation in assessment of validity. *Emerg Med J.* 2017;34:703–10.
3. Kristensen M, Iversen AKS, Gerds TA, Østervig R, Linnet JD, Barfod C, et al. Routine blood tests are associated with short term mortality and can improve emergency department triage: a cohort study of >12,000 patients. *Scand J Trauma Resusc Emerg Med.* 2017;25:115.
4. Seymour CW, Cooke CR, Wang Z, Kerr KF, Yealy DM, Angus DC, et al. Improving risk classification of critical illness with biomarkers: a simulation study. *J Crit Care.* 2013;28:541–8.
5. Schuetz P, Hausfater P, Amin D, Amin A, Haubitz S, Faessler L, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. *Crit Care.* 2015;19:377.
6. Iversen K, Gotze JP, Dalsgaard M, Nielsen H, Boesgaard SSS, Bay M, et al. Risk stratification in emergency patients by copeptin. *BMC Med.* 2014;12:80.
7. Rasmussen LJH, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. *Emerg Med J.* 2016;33:769–75.
8. Haupt TH, Petersen J, Ellekilde G, Klausen HH, Thorball CW, Eugen-Olsen J, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson comorbidity index in the acutely admitted medical patient: a prospective observational study. *Crit Care.* 2012;16:R130.
9. Østervig RM, Køber L, Forberg JL, Rasmussen LS, Eugen-Olsen J, Iversen K. suPAR – a future prognostic biomarker in emergency medicine. *J Emerg Med.* 2015;48:642–3.
10. Sandø A, Schultz M, Eugen-Olsen J, Rasmussen LS, Køber L, Kjølner E, et al. Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster

- randomized interventional trial. *Scand J Trauma Resusc Emerg Med.* 2016;24:100.
11. Schultz M, Rasmussen LJH, Andersen MH, S SJ, Falkentoft Alexander AM, et al. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III). *Scand J Trauma Resusc Emerg Med.* 2018;26:69.
 12. Skriver C, Lauritzen MMP, Forberg JL, Gaardboe-Poulsen OB, Mogensen CB, Hansen CL, et al. [Triage quickens the treatment of the most sick patients]. *Ugeskr Laeger* 2011;173:2490–2493. <http://www.ncbi.nlm.nih.gov/pubmed/21975184>. Accessed 4 Dec 2018.
 13. Nordberg M, Lethvall S, Castrén M. The validity of the triage system ADAPT. *Scand J Trauma Resusc Emerg Med.* 2010;18(Suppl 1):P36.
 14. Göransson KE, Von Rosen A. Interrater agreement: a comparison between two emergency department triage scales. *Eur J Emerg Med.* 2011;18:68–72.
 15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics.* 1988;44:837–45.
 16. Youden WJ. Index for rating diagnostic tests. *Cancer.* 1950;32–5.
 17. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for statistical computing; 2017. <https://www.r-project.org/>. Accessed 9 Apr 2018.
 18. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics.* 2011;12:77.
 19. Brabrand M, Folkestad L, Clausen NG, Knudsen T, Hallas J. Risk scoring systems for adults admitted to the emergency department: a systematic review. *Scand J Trauma Resusc Emerg Med.* 2010;18(8):8.
 20. Rasmussen LJH, Ladelund S, Haupt TH, Ellekilde GE, Eugen-Olsen J, Andersen O. Combining National Early Warning Score with Soluble Urokinase Plasminogen Activator Receptor (suPAR) improves risk prediction in acute medical patients. *Crit Care Med.* 2018;46:1961–8. <https://doi.org/10.1097/CCM.0000000000003441>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

